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InvasionMUC1 is a membrane-bound mucin known to participate in tumor proliferation. It has been shown that MUC1
pattern of expression ismodiﬁed during esophageal carcinogenesis, with a progressive increase frommetaplasia
to adenocarcinoma. The principal cause of development of esophageal adenocarcinoma is gastro-esophageal re-
ﬂux andMUC1was previously shown to be up-regulated by several bile acids present in reﬂux. In this report, our
aimwas thus to determinewhether MUC1 plays a role in biological properties of human esophageal cancer cells.
For that, a stable MUC1-deﬁcient esophageal cancer cell line was established using a shRNA approach. In vitro
(proliferation, migration and invasion) and in vivo (tumor growth following subcutaneous xenografts in SCID
mice) biological properties of MUC1-deﬁcient cells were analyzed. Our results show that esophageal cancer
cells lackingMUC1were less proliferative andhaddecreasedmigration and invasion properties. These alterations
were accompanied by a decreased activity of NFKB p65, Akt and MAPK (p44/42, JNK and p38) pathways. MCM6
and TSG101 tumor-associated markers were also decreased. Subcutaneous xenografts showed a signiﬁcant de-
crease in tumor size when cells did not express MUC1. Altogether, the data indicate that MUC1 plays a key role
in proliferative, migrating and invasive properties of esophageal cancer cells as well as in tumor growth promo-
tion. MUC1 mucin appears thus as a good therapeutic target to slow down esophageal tumor progression.ovski, 59045 Lille cedex, France.
an Seuningen).© 2014 Elsevier B.V. All rights reserved.1. Introduction
Esophageal cancer is the 7th cause of death due to cancer worldwide
and esophageal adenocarcinoma (EA) incidence has been increasing
importantly for the last 40 years [1,2]. Despite the use of a multimodal
therapy with surgery more and less chemo- or radiotherapy to treat
this cancer, the prognosis remains poor with 15% to 25% of 5-year over-
all survival [2,3]. It is mainly due to a late diagnosis with advanced stage
of the disease and resistance to schemes of chemotherapy and/or radio-
therapy [2,4].
The duodeno-gastro-esophageal reﬂux responsible for chronic ex-
posure of the distal esophagus has been demonstrated to have a major
participation in EA initiation [5–7]. This exposure induces the initiation
of early carcinogenetic lesion called Barrett esophagus (BE). BE is char-
acterized by the replacement of a normal epithelium by an intestinaland/or gastric type metaplasia and by the increase of the mucus-
secreting cells [8]. Under the effects of this chronic exposure to the re-
ﬂux, BE lesions may evolve to low-grade then high-grade dysplasia
and ﬁnally to EA [9].We previously showed in a rat surgicalmodel of in-
duced gastro-duodenal reﬂux that the duodenal component of the re-
ﬂux plays a signiﬁcant role in initiating the carcinogenic sequence,
whereas duodenogastric juice is more involved in progression to EA
[10].
In order to improve patient therapy and prognosis, there is an urgent
need to better understand the molecular mechanisms and identify new
actors involved during this carcinogenesis in order to further ﬁnd new
targets for early diagnosis or newmolecules that could be used as ther-
apeutic targets.
Among these potential targets, we previously identiﬁed the mucin
MUC1 [11–13]. The mucin MUC1, which is a large transmembrane O-
glycoprotein, is overexpressed in EA [12], whereas it is expressed at a
very low level in normal esophageal epithelium [12,14,15]. This altered
pattern of expression of MUC1 is often associated with protumorigenic
activities of MUC1 in many epithelial cancers that include activation of
proliferative pathways, tumor progression and participation inmetasta-
sis formation [11,16,17].
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at the transcriptional level by bile acids responsible for the reﬂux lead-
ing to EA [13] and in vivo that MUC1 overexpression follows esophageal
carcinogenesis [10], we undertook in this work to study the roles of
MUC1 on the biological properties of human EA cells. Our results indi-
cate that MUC1 is a therapeutic target of interest to slow down esopha-
geal tumorigenesis and to propose new therapeutic approaches to
better treat this cancer.
2. Material and methods
2.1. Cell culture
The OE33 esophageal adenocarcinomatous cell line was cultured as
described previously [18]. To study the role of MUC1, a stable cell line
deﬁcient in MUC1 (shMUC1) was established following a retro-viral in-
fection using a pRetroSuper plasmid (SABiosciencesTM) containing a
sequence targeting MUC1 (forward primer (FP):GATCCCCGGTACCA
TCAATGTCCACG-TTCAAGAGA-CGTGGACATTGATGGTACC-TTTTTGGA
AA; reverse primer (RP): AGCTTTTCCAAAAA-GGTACCATCAATGTCC
ACG-TCTCTTGAA-CGTGGACATTGATGGTACC-GGG) [19]. The control
cells (Mock) were infected with the corresponding empty vector. All
the results presented in this study correspond to themean of two repre-
sentative clones, shMUC1-1 and shMUC1-2, compared to two represen-
tative control clones, Mock1 and Mock2.
2.2. Small Interfering RNA (siRNA) assays
OE33 cellswere transfectedwith speciﬁc NFKB p65, PI3K,MMP3 and
MMP13 siRNA (ON-TARGET plus SMART pool siNFKB2, ON-TARGET
plus SMART pool siPI3KCG, ON-TARGET plus SMART pool siMMP3 and
ON-TARGET plus SMART pool siMMP13) from Dharmacon (Epson, Sur-
rey, UK) following the protocol described previously [20]. Controls were
included using either a Non-Targeting siRNA (NT) or the transfection
agent alone (Dharmafect 1, Dharmacon).
2.3. RNA extraction and reverse transcriptase-polymerase chain reaction
(RT-PCR)
Total RNA was isolated and puriﬁed from tissues using the
NucleoSpin RNA L kit (Macherey-Nagel, Duren, Germany) as described
in the manufacturer's protocol. The RNA quantity was determined by
measuring the optical density at 260 nm with a NanoDrop 1000 spec-
trophotometer (Thermo Scientiﬁc, Pittsburgh, Penn). Total RNA (1 μg)
was used to prepare cDNA using oligodT (1 μl) and recombinant
Retro-Transcriptase Moloney Murine Leukemia Virus (M-MLV) (1 μl)
(Promega, Charbonnières, France). PCR was performed on cDNA (5 μl),
using speciﬁc pairs of primers: 28S, PI3K (FP: GAAGCCATTGAGAAGA
AAGGA, RP: GAGGTGTTCAGTATTATCAGAGC), NFKB p65 (FP: GAAGAA
GCGAGACCTGGAG, RP: TCCGGAACACAATGGCCAC) (MWG-Biotech
(Ebersberg, Germany). For each gene, analyses were performed three
times in triplicate. 28S was used as an internal control. PCR products
(20 μl) were separated on a 1.5% (w/v) agarose gel containing ethidium
bromide run in 1× Tris borate EDTA. The gene of interest/28S ratio was
calculated after scanning DNA bands with the Gel Analyst-gel Smart
software (Claravision, Orsay, France).
2.4. Protein extraction and expression
Total protein extraction and expression using Western blotting were
realized as described in [20]. Antibodies used were purchased from
Sigma [β-actin (A-5441 at 1/5000)], Abcam [TSG101 (ab83 at 1/500),
MMP13 (ab39012 at 1/500) andMCM6 (ab4458 at 1/2000)], Cell Signal-
ing Technology [PI3K (at 1/1000), Akt (clone C67E7 at 1/500), phospho-
Akt (Ser473, clone D9E at 1/500), NFKB p65 (clone E498 at 1/500),
phospho-NFKB p65 (Ser536, clone 93H1 at 1/500)], p44/42 (cloneI37F5, 1/500), phospho-p44/42 (Thr202/Tyr204, clone 20G11, 1/500),
JNK (clone 56G8, 1/500), phospho-JNK (Thr183/Tyr185, #9251, dilution
1/500), p38 (#9212, dilution 1/1000) and phospho-p38 (Thr180/Tyr182,
clone D3F9, 1/1000). MUC1 antibody (M8 at 1/250) was a gracious
gift from Pr Dallas Swallow (University College London). Peroxi-
dase-conjugated secondary antibodies (Pierce) were used and the
chemoluminescence was visualized using a LAS4000 apparatus
(Fujiﬁlm). The protein of interest/β-actin ratio was calculated after
scanning protein bands with the Gel Analyst-gel Smart software
(Claravision, Orsay, France).2.5. Cell proliferation
The 1.5 × 105 cells were plated in 6-well plates and were counted
daily during 6 days using a Malassez Chamber. Each experiment was
carried out three times in triplicate.2.6. Cell migration and invasion
The 2 × 105 cells were plated in 96-well plate. At conﬂuence, a
wound was created using the 96-pin WoundMaker device (Essen Bio-
science). The plate was then placed in an incubator into an Incucyte™
chamber apparatus (Essen Bioscience) at 5% CO2 and 37 °C. Every 2 h,
a picture of the wounds was taken and the wound closure percentages
were calculated every 12 h, from 0 to 36 h. Cell invasion and migration
was also studied using Boyden Chambers coated or not with Matrigel®
(BD Bioscience), respectively. Cells that went through the matrix were
counted 48 h after the cells had been plated. The invasion indexwas cal-
culated as recommended by the manufacturer (Invasion/Migration
ratio). Each experiment was carried out three times in triplicate.2.7. Subcutaneous xenografts
Subcutaneous xenografts of OE33 shMUC1 and Mock cells into SCID
mice were performed with 150 μl of RPMI 1640 medium (Invitrogen)
containing 4 × 106 cells and 150 μl of Matrigel® (BD 354262, BD Biosci-
ence). The tumor progression was followed weekly, and the tumor vol-
umes (w/l2) were calculated in cm3. For each cell clone, 10 mice were
injected. All procedureswere in accordancewith the guideline of animal
care committee (Comité Ethique Expérimentation Animal Nord Pas-de-
Calais, #AF042008).2.8. Immunohistochemistry
The expression levels of MUC1 (1/50), Akt (1/500), NFKB p65
(1/500), TSG101 (1/100) and MCM6 (1/100) in human normal esoph-
ageal tissues, BE and EA lesions were studied by automatic (automated
immunostainer ES, Ventana Medical System, Strasbourg, France) [18]
andmanual [21] immunohistochemistry (IHC), respectively. Antibodies
against NFKB p65 (sc-7151), TSG101 (M-19) and MCM6 (sc-9843)
were purchased from Santa Cruz Biotechnology. Positive controls
were included by staining tissues known to express the protein of inter-
est, and negative controls were run with 1× D-PBS instead of primary
antibodies.2.9. Statistics
The statistical analyses were carried out using both Excel and
GraphPad 4.0 softwares (GraphPad softwares Inc., La Jolla, USA). The
differences in the means of samples were analyzed using a Student t
test or a one-way ANOVA test with selected comparison using the
Tukey post hoc test with differences less than 0.05 considered as statis-
tically signiﬁcant (*) (**p b 0.01 and ***p b 0.001).
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3.1. In vitro biological properties of MUC1-deﬁcient OE33 cells
To study the roles of MUC1 in the EA tumor progression, we
established a stable OE33 shMUC1 cell line using a shRNA approach
(Fig. 1A). The complete loss of MUC1 protein expression in the
shMUC1 cells was conﬁrmed by Western blotting when compared to
the control cells (Mock). The capacity of OE33 cells to proliferate in ab-
sence or presence of MUC1 was tested over a period of 6 days (Fig. 1B).
The results indicate that MUC1-deﬁcient cells (shMUC1) signiﬁcantly
proliferate less than Mock cells as of day 4 (p = 0.0158), and this re-
duced proliferation is sustained until day 6 (p = 0.0002). The role of
MUC1 in cell migration was studied using a wound-healing test
(Fig. 1C). We showed that in MUC1-deﬁcient cells (shMUC1), the mi-
gration was impaired as of 12 h (p = 0.0179) after the wound
was made when compared to Mock cells. This was sustained until 36 h
(p = 0.0025). The role of MUC1 in OE33 capacity to invade a matrix
was studied using Boyden Chamber coated with Matrigel® (Fig. 1D).
The results indicate that MUC1-deﬁcient cells are signiﬁcantly less inva-
sive compared to Mock cells (p= 0.0137), with a reduction of the inva-
sion index of 31% compared to the controls. This decreased invasion
was correlated to a decreased expression of MMP13 in MUC1-deﬁcient
cells (Fig. 1A). Moreover, OE33 cells transfected with MMP13 siRNA
were less invasive (Fig. 1E). This was not found for MMP3 (not shown).Fig. 1. In vitro biological properties of MUC1-deﬁcient OE33 cells. (A) Expression of MUC1 and
(gray line) andMock (black line) cell proliferation in vitro. Countingswere carried out withMal
dent t test). (C) shMUC1 and Mock OE33 cell migration was studied by wound-healing test. Th
sentation of the wound closure in percentage from T0 to T36h. Comparison of the shMUC
(D) Representation of the invasion index of Mock (black) and shMUC1 (gray) cells using Boyd
number of invasive cells reported to the number of migrating cells. *p ≤ 0.05 (Student t test)
non targeting (NT) siRNA (dark gray) or MMP13 siRNA using Boyden Chambers coated with MKnocking down expression of MMP3 or MMP13 had no impact on OE33
cell proliferation and migration properties (Fig. S1A and B).
3.2. In vivo biological properties of MUC1-deﬁcient OE33 cells
Having shown that MUC1-deﬁcient cells were less proliferative, less
invasive and less migrating than Mock cells in vitro, we undertook to
study the impact of MUC1 absence on tumor growth in vivo by
performing subcutaneous xenografts of shMUC1 cells in SCID mice
(Fig. 2). At 6 weeks post-injection, the shMUC1 tumors were much
smaller (shMUC1-1: 0.57 ± 0.07 and shMUC1-2: 0.49 ± 0.16 cm3)
than theMock cell tumors (1.76± 0.07 cm3)with a 68% and 72% reduc-
tion, respectively. This difference between the tumor volumeswashigh-
ly signiﬁcant between the Mock and the shMUC1-1 cells (p b 0.01)
and extremely signiﬁcant between the Mock and the shMUC1-2 cells
(p b 0.001).
3.3. MUC1 deﬁciency impairs NFKB p65, Akt and MAPK pathways
Having shown thatMUC1deﬁciency impairs proliferation,migration
and invasion properties of OE33 cells, we undertook to study the intra-
cellularmechanisms and signalling pathways that could mediate MUC1
effects. Our results indicate decreased activation of NFKB p65 and Akt
pathway in shMUC1 cells compared to Mock cells as well as decreased
activation of the three major MAPK pathways (p44/42, JNK and p38)MMP13 in Mock and in shMUC1 OE33 cells by Western blotting. (B) Analysis of shMUC1
assey Chambers andwere performed daily during 6 days. *p≤ 0.05 and ***p≤ 0.001 (Stu-
e photographies of the wound closures were taken at 0 h and 36 h post-wounding. Repre-
1 (gray line) to the Mock (black line) cells. *p ≤ 0.05 and **p ≤ 0.01 (Student t test).
en Chambers coated with Matrigel®. The invasion index is the ratio corresponding to the
. (E) Representation of the invasion index of Mock cells (black), or cells transfected with
atrigel®. ***p ≤ 0.001 (Student t test).
Fig. 2. In vivo role of MUC1 on tumor growth. Means of tumor volumes in cm3 obtained
6 weeks after SC injections of Mock or shMUC1 cells in SCID mice. **p ≤ 0.01 and
***p ≤ 0.001 (one-way ANOVA with Tukey post hoc).
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pathways in cell proliferation was further conﬁrmed using a siRNA
approach with a signiﬁcant decreased proliferation following siRNA
treatment. No effect was found on cell migration (Fig. S1B). Correlation
betweenMUC1, NFκB p65 and Akt expression was further conﬁrmed in
human esophageal tissueswith immunohistochemical staining, indicat-
ing increased of expression of MUC1, NFKB p65 and Akt in BE and EA
compared to normal squamous epithelium (Fig. 4B).
Having previously found that the Tumor susceptibility gene 101
(TSG101) and the minichromosome maintenance complex-6 gene
(MCM6) tumor-associated proteins were overexpressed in an MUC1-
expressing rat model of esophageal cancer [10], we checked whetherFig. 3. Impact of MUC1 deﬁciency on NFKB p65, Akt andMAPK pathways. (A) Expression of NFK
JNK, phospho-JNK, p38 and phospho-p38) and β-actin inMock and shMUC1 OE33 cells byWest
proliferation after siRNA treatment. (C) Expression of PI3K mRNA by RT-PCR and in vitro ana
Malassey Chambers and was performed daily during 6 days. *p ≤ 0.05 and **p ≤ 0.01.these two tumor markers were also altered in human OE33 MUC1-
deﬁcient cells and in human esophageal tissues. Accordingly, we
found decreased expression of these two proteins in shMUC1 cells
(Fig. 4A). Immunohistochemical studies in human esophageal tissues
indicated expression of MCM6 in the nucleus of epithelial cells of nor-
mal squamous epithelium (Fig. 4B). In BE and EA, MCM6was expressed
in the nuclei of epithelial cells constituting BE, with a higher number of
labeled cells at the bottom of the glands compared to the surface villi
(Fig. 4B). In EA, MCM6 was also expressed in the nuclei of epithelial
cells lining the pools of mucus. Whereas TSG101 was not expressed in
normal esophagus, we observed TSG101 expression in the cytoplasm
of basal cells in both BE and EA (Fig. 4B). As expected, MUC1 mucin
was expressed in epithelial cells of the superﬁcial layers of the normal
squamous epithelium and overexpressed in the early stage of BE and
sustained in EA.4. Discussion
In this report, we show that the MUC1 mucin plays a role in both
in vitro (proliferation, migration and invasion) and in vivo (tumor
growth) properties of esophageal adenocarcinomatous cells. Our results
suggest that invasive properties of MUC1 may be mediated by the
MMP13 metalloprotease. In support of this ﬁnding, previous data
showed thatMUC1 inducesmetastasis in esophageal squamous cell car-
cinoma (SCC) by up-regulating MMP13 [22]. Other results showed that
MMP13 has a key role in extracellular matrix degradation and tumor
metastasis and that its overexpression was reported in esophageal SCC
and was related to cancer aggressiveness [23]. MMP13 appears thus as
a central element in invasive properties of esophageal cancer cells.
Furthermore, it has been shown that MUC1 is an oncoprotein in-
volved in many epithelial cancers [11]. In EA, the expression of MUC1
is progressively increased frommetaplasia to adenocarcinoma, suggest-
ing a potential role in degeneration of BE into adenocarcinoma [14].B p65, phospho-NFKB p65, PI3K, Akt, phospho-Akt andMAPKs (p44/42, phospho-p44/42,
ern blotting. (B) Expression ofNFKB p65mRNA by RT-PCR and in vitro analysis of OE33 cell
lysis of OE33 cell proliferation after siRNA treatment. Cell counting was carried out with
Fig. 4. Expression of MUC1 and tumor-associated proteins in humanMUC1-deﬁcient cells and in human esophageal tissues. (A) Expression of TSG101, MCM6 and β-actin inMock and in
shMUC1 OE33 cells by Western blotting. Protein intensity is reported to the β-actin expression. *p ≤ 0.05 and ***p ≤ 0.001. (B) Immunohistochemical staining of MUC1, Akt, NFKB p65,
MCM6 and TSG101 in human esophageal tissues: normal esophagus ×100, Barrett esophagus (BE) ×100, esophageal adenocarcinoma (EA) ×100, inserts ×200.
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anti-adhesive activity [24,25] and to its binding properties to β-
catenin and other family members [26], (ii) in cell interaction and (iii)
in transcriptional regulation [27]. Our results suggest that the increase
ofMMP13 expressionmay be thus an additionalmechanism to promote
MUC1 invasive properties.
To go further, we showed that absence of MUC1 in EA cells was cor-
related to the decreased expression of tumor-associated proteins
TSG101 and MCM6, suggesting a link between MUC1 and these two
proteins. Thiswas also accompanied by an impaired proliferation capac-
ity of EA cells. Since TSG101 is known to be involved in numerous cellu-
lar processes including apoptotic resistance [28] and G1/S Cell cycle
checkpoint control [29] and MCM6 being involved in cell cycle control
[30], these two proteinsmay be considered as partners of MUC1 to con-
vey EA cell proliferative capacities.
We also showed that the alteration of MUC1 expression in EA cells
profoundly impaired NFκB p65 andMAPK (p44/42, JNK and p38) path-
ways. Recently, it has been shown in colon cancer cells that MUC1 could
inhibit apoptosis via activating JNK1 pathway in response to genotoxic
anticancer agents such as cisplatin [31]. This suggests that MUC1, via
theMAPK pathways, could perhaps be a target of choice to ﬁght against
chemoresistance in EA. In a recent study, Paterson et al. demonstrated
that the MAPK pathway was commonly activated in esophago-gastric
cancer and that the constitutively active receptor tyrosine kinases
(RTK) could be identiﬁed on a patient using RTK array analysis. This
could be considered as a ﬁrst step for a personalised treatment by
targeting the signalling pathway in EA [32].
The alteration of NFκB p65 pathway consecutively to MUC1 deple-
tion altered EA cell proliferation properties. This is in agreement with
increasedNFκB p65 expression observed in BE and EA. The NFκB p65 in-
creased expression in EA has been correlated to chemoradiationresistance [33]. So MUC1 could potentially be considered as a factor of
chemoresistance by the activation of the NFκB p65 pathway.
Furthermore, previous studies have shown that tumor cells express-
ingMUC1 exhibit an increased capacity to resist the effect of chemother-
apeutic drugs. Indeed, MUC1 blocks DNA damage-induced apoptosis by
several mechanisms: (i) MUC1 C-terminal subunit is localized to themi-
tochondrial outer membrane to attenuate release of mitochondrial
apoptogenic factors [34] and binds directly to Bax to block its function
in activating the mitochondrial death pathway [35]; (ii) MUC1 seques-
ters c-Abl in the cytoplasm and inhibits apoptosis in response to
genotoxic anticancer agents [36].
Whereas in esophageal SCC, a high level of MUC1 expressionwas re-
ported to be correlatedwith lymph nodemetastasis and associatedwith
a poor prognosis [23], we previously did not show any correlation be-
tween the level of MUC1 expression in EA and histopathological vari-
ables, recurrence or survival in a series of 52 patients [15]. Even if
MUC1 may not serve as a potential biomarker in EA, our study suggests
that MUC1 plays a role in EA cell proliferation and invasiveness and
could be also considered as a potential therapeutic target for EA patients
as a factor of chemoresistance.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.06.021.
Acknowledgments
We thank Pr. Dallas Swallow (University College, MRC, London) for
her gracious gift of the M8 MUC1 monoclonal antibody and Dr. David
Bernard (Inserm UMR1052/CNRS5286, Centre Léon Bérard, Lyon,
France) for his help in establishing the stable MUC1-deﬁcient cells. We
also thank Brigitte Hémon, Bérangère Barbot, Wassila Igoudgil and
Belinda Duchêne for their excellent technical help. This work was
2437C. Gronnier et al. / Biochimica et Biophysica Acta 1843 (2014) 2432–2437supported by grants from La Fondation pour la Recherche Médicale
(Equipe FRM 2009, CM) and from SIRIC ONCOLille, Grant INCa-
DGOS-Inserm 6041. Emilie Bruyère is the recipient of a PhD fellow-
ship from Le Centre Hospitalier Régional Universitaire de Lille and
Région Nord-Pas de Calais. Fatima Lahdaoui is the recipient of a
fellowship from SIRIC ONCOLille, grant INCa-DGOS-Inserm 6041.
Isabelle Van Seuningen is the recipient of a Contrat Hospitalier de
Recherche Translationnelle/CHRT 2010, AVIESAN.
References
[1] J. Ferlay, D.M. Parkin, E. Steliarova-Foucher, Estimates of cancer incidence and mor-
tality in Europe in 2008, Eur. J. Cancer 46 (2010) 765–781.
[2] J.D. Luketich, A. Pennathur, O. Awais, R.M. Levy, S. Keeley, M. Shende, N.A. Christie, B.
Weksler, R.J. Landreneau, G. Abbas, M.J. Schuchert, K.S. Nason, Outcomes after min-
imally invasive esophagectomy: review of over 1000 patients, Ann. Surg. 256
(2012) 95–103.
[3] C.Mariette, G. Piessen, N. Briez, C. Gronnier, J.P. Triboulet, Oesophagogastric junction
adenocarcinoma: which therapeutic approach? Lancet Oncol. 12 (2011) 296–305.
[4] C. Mariette, G. Piessen, J.P. Triboulet, Therapeutic strategies in oesophageal carcino-
ma: role of surgery and other modalities, Lancet Oncol. 8 (2007) 545–553.
[5] M. Fein, J. Maroske, K.H. Fuchs, Importance of duodenogastric reﬂux in gastro-
oesophageal reﬂux disease, Br. J. Surg. 93 (2006) 1475–1482.
[6] W.K. Kauer, J.H. Peters, T.R. DeMeester, H. Feussner, A.P. Ireland, H.J. Stein, R.J.
Siewert, Composition and concentration of bile acid reﬂux into the esophagus of pa-
tients with gastroesophageal reﬂux disease, Surgery 122 (1997) 874–881.
[7] C.P. Wild, L.J. Hardie, Reﬂux, Barrett's oesophagus and adenocarcinoma: burning
questions, Nat. Rev. Cancer 3 (2003) 676–684.
[8] B.J. Colleypriest, S.G. Ward, D. Tosh, How does inﬂammation cause Barrett's meta-
plasia? Curr. Opin. Pharmacol. 9 (2009) 721–726.
[9] A.T. Prach, T.A. MacDonald, D.A. Hopwood, D.A. Johnston, Increasing incidence of
Barrett's oesophagus: education, enthusiasm, or epidemiology? Lancet 350 (1997)
933.
[10] C. Gronnier, E. Bruyere, G. Piessen, N. Briez, J. Bot, D. Buob, E. Leteurtre, I. Van
Seuningen, C. Mariette, Operatively induced chronic reﬂux in rats: a suitable
model for studying esophageal carcinogenesis? Surgery 154 (2013) 955–967.
[11] N. Jonckheere, I. Van Seuningen, The membrane-bound mucins: how large O-
glycoproteins play key roles in epithelial cancers and hold promise as biological
tools for gene-based and immunotherapies, Crit. Rev. Oncog. 14 (2008) 177–196.
[12] N. Jonckheere, I. Van Seuningen, The membrane-bound mucins: from cell signalling
to transcriptional regulation and expression in epithelial cancers, Biochimie 92
(2010) 1–11.
[13] C. Mariette, G. Piessen, E. Leteurtre, B. Hemon, J.P. Triboulet, I. Van Seuningen, Acti-
vation of MUC1mucin expression by bile acids in human esophageal adenocarcino-
matous cells and tissues is mediated by the phosphatidylinositol 3-kinase, Surgery
143 (2008) 58–71.
[14] E. Bruyere, I. Van Seuningen, Mucins and Esophageal Carcinogenesis: New Bio-
markers and/or Therapeutic Targets? in: Leon V. Berhardt (Ed.), Advances in Medi-
cine and Biology, 23, Nova Science Publishers, Inc., Hauppage, NY, 2011, pp.
145–157.
[15] G. Piessen, A.Wacrenier, N. Briez, J.P. Triboulet, I. Van Seuningen, C.Mariette, Clinical
impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocar-
cinoma, J. Clin. Pathol. 62 (2009) 1144–1146.
[16] M.A. Hollingsworth, B.J. Swanson, Mucins in cancer: protection and control of the
cell surface, Nat. Rev. Cancer 4 (2004) 45–60.
[17] D.W. Kufe, Mucins in cancer: function, prognosis and therapy, Nat. Rev. Cancer 9
(2009) 874–885.[18] C. Mariette, M. Perrais, E. Leteurtre, N. Jonckheere, B. Hemon, P. Pigny, S. Batra, J.P.
Aubert, J.P. Triboulet, I. Van Seuningen, Transcriptional regulation of human mucin
MUC4 by bile acids in oesophageal cancer cells is promoter-dependent and involves
activation of the phosphatidylinositol 3-kinase signalling pathway, Biochem. J. 377
(2004) 701–708.
[19] P. Mukherjee, T.L. Tinder, G.D. Basu, S.J. Gendler, MUC1 (CD227) interacts with lck
tyrosine kinase in Jurkat lymphoma cells and normal T cells, J. Leukoc. Biol. 77
(2005) 90–99.
[20] G. Piessen, N. Jonckheere, A. Vincent, B. Hemon, M.P. Ducourouble, M.C. Copin, C.
Mariette, I. Van Seuningen, Regulation of thehumanmucinMUC4by taurodeoxycholic
and taurochenodeoxycholic bile acids in oesophageal cancer cells ismediated byhepa-
tocyte nuclear factor 1alpha, Biochem. J. 402 (2007) 81–91.
[21] M. van der Sluis, M.H. Melis, N. Jonckheere, M.P. Ducourouble, H.A. Buller, I. Renes, A.
W. Einerhand, I. Van Seuningen, The murine Muc2 mucin gene is transcriptionally
regulated by the zinc-ﬁnger GATA-4 transcription factor in intestinal cells, Biochem.
Biophys. Res. Commun. 325 (2004) 952–960.
[22] Q. Ye, Z. Yan, X. Liao, Y. Li, J. Yang, J. Sun, T. Kawano, X. Wang, Z. Cao, Z. Wang, L.
Huang, MUC1 induces metastasis in esophageal squamous cell carcinoma by upreg-
ulating matrix metalloproteinase 13, Lab. Invest. 91 (2011) 778–787.
[23] T. Etoh, H. Inoue, Y. Yoshikawa, G.F. Barnard, S. Kitano, M. Mori, Increased expres-
sion of collagenase-3 (MMP-13) and MT1-MMP in oesophageal cancer is related
to cancer aggressiveness, Gut 47 (2000) 50–56.
[24] S. Satoh, Y. Hinoda, T. Hayashi, M.D. Burdick, K. Imai, M.A. Hollingsworth, Enhance-
ment of metastatic properties of pancreatic cancer cells by MUC1 gene encoding an
anti-adhesion molecule, Int. J. Cancer 88 (2000) 507–518.
[25] E. van de Wiel-van Kemenade, M.J. Ligtenberg, A.J. de Boer, F. Buijs, H.L. Vos, C.J.
Melief, J. Hilkens, C.G. Figdor, Episialin (MUC1) inhibits cytotoxic lymphocyte-
target cell interaction, J. Immunol. 151 (1993) 767–776.
[26] J. Ren, Y. Li, D. Kufe, Protein kinase C delta regulates function of the DF3/MUC1 car-
cinoma antigen in beta-catenin signaling, J. Biol. Chem. 277 (2002) 17616–17622.
[27] K.L. Carraway, V.P. Ramsauer, B. Haq, C.A. Carothers Carraway, Cell signaling through
membrane mucins, Bioessays 25 (2003) 66–71.
[28] D.C. Liu, Z.L. Yang, S. Jiang, Identiﬁcation of PEG10 and TSG101 as carcinogenesis,
progression, and poor-prognosis related biomarkers for gallbladder adenocarcino-
ma, Pathol. Oncol. Res. 17 (2011) 859–866.
[29] M.J. Carstens, A. Krempler, A.A. Triplett, M. Van Lohuizen, K.U. Wagner, Cell cycle ar-
rest and cell death are controlled by p53-dependent and p53-independent mecha-
nisms in Tsg101-deﬁcient cells, J. Biol. Chem. 279 (2004) 35984–35994.
[30] P.S. Frisa, J.W. Jacobberger, Cytometry of chromatin bound Mcm6 and PCNA iden-
tiﬁes two states in G1 that are separated functionally by the G1 restriction point,
BMC Cell. Biol. 11 (2010) 26.
[31] Q. Chen, D. Li, J. Ren, C. Li, Z.X. Xiao, MUC1 activates JNK1 and inhibits apoptosis
under genotoxic stress, Biochem. Biophys. Res. Commun. 440 (2013) 179–183.
[32] A.L. Paterson, N.B. Shannon, P. Lao-Sirieix, C.A. Ong, C.J. Peters, M. O'Donovan, R.C.
Fitzgerald, A systematic approach to therapeutic target selection in oesophago-
gastric cancer, Gut 62 (2013) 1415–1424.
[33] M.M. Abdel-Latif, D. Kelleher, J.V. Reynolds, Potential role of NF-kappaB in esophage-
al adenocarcinoma: as an emerging molecular target, J. Surg. Res. 153 (2009)
172–180.
[34] J. Ren, N. Agata, D. Chen, Y. Li, W.H. Yu, L. Huang, D. Raina, W. Chen, S. Kharbanda, D.
Kufe, Human MUC1 carcinoma-associated protein confers resistance to genotoxic
anticancer agents, Cancer Cell 5 (2004) 163–175.
[35] R. Ahmad, M. Alam, H. Rajabi, D. Kufe, The MUC1-C oncoprotein binds to the BH3
domain of the pro-apoptotic BAX protein and blocks BAX function, J. Biol. Chem.
287 (2012) 20866–20875.
[36] D. Raina, R. Ahmad, S. Kumar, J. Ren, K. Yoshida, S. Kharbanda, D. Kufe, MUC1
oncoprotein blocks nuclear targeting of c-Abl in the apoptotic response to DNA
damage, EMBO J. 25 (2006) 3774–3783.
